Merck
-
KEYTRUDA Plus WELIREG Combination Adjuvant Therapy Shows 28% Reduced Risk of Recurrence or Death in Early-Stage Kidney Cancer
Merck’s new adjuvant therapy combining KEYTRUDA and WELIREG shows a 28% reduced risk of recurrence or death in early-stage kidney cancer patients. This promising data could significantly expand the use of Merck’s key oncology drugs, potentially reshaping the competitive landscape in the lucrative kidney cancer market. Analysts are scrutinizing long-term data and market implications.
-
Merck’s Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Significant LDL-C Reduction in Phase 3 CORALreef Lipids Trial
Merck’s Phase 3 CORALreef Lipids trial revealed that enlicitide, an investigational oral PCSK9 inhibitor, significantly reduced LDL-C levels by 55.8% in adults with or at risk for ASCVD. The study demonstrated sustained reductions at one year and improvements in other lipid parameters. Enlicitide’s safety profile was comparable to placebo, with high treatment adherence. The oral formulation may address unmet needs in ASCVD management due to the availability of current injectable PCSK9 inhibitors. Merck plans to seek regulatory approval based on these findings and other CORALreef trials.
-
ACIP Recommends Merck’s ENFLONSIA™ (clesrovimab-cfor) for RSV Prevention in Infants
Merck’s ENFLONSIA (clesrovimab-cfor), a new monoclonal antibody for RSV prevention in infants under eight months, has received a positive recommendation from the CDC’s ACIP. Approved by the FDA, ENFLONSIA aims to protect against RSV lower respiratory tract disease, with ordering for the 2025-2026 season starting in July. The standardized dose provides rapid, lasting protection for a typical five-month RSV season, with potential accessibility via the Vaccines for Children Program.
